Phase I tolerability, pharmacokinetics and preliminary efficacy of ACH 1625 in volunteers and hepatitis C-infected patients

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Apr 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sovaprevir (Primary)
Indications Hepatitis C
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use

03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
15 Sep 2010 An abstract has been accepted as a late-breaking poster at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD), according to an Achillion Pharmaceuticals media release.
11 May 2010 Additional preliminary results from the phase 1b part of the trial have been reported in a Achillion Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com